Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 29, 2016
Pharmacy Choice - News - Generic Drugs - June 29, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 53     Next >>     Go To Page:

6/29/16 - Charles River Acquires Blue Stream Laboratories [Arab News (Saudi Arabia)]
Charles River Laboratories announced on June 27, 2016 that it has acquired Blue Stream Laboratories, an analytical contract research organization supporting the development of complex biologics and biosimilars. This acquisition will combine Blue Stream and Charles Rivers existing discovery, safety assessment, and biologics capabilities, Charles...
6/29/16 - Mayne Pharma to Acquire US Generics Product Portfolio from Teva and Allergan [Daily Star, The (Lebanon)]
Mayne Pharma entered into an agreement to acquire 37 approved, and five FDA- filed products from Teva Pharmaceuticals and Allergan for cash considerations of $652 million, Mayne said in a June 28, 2016 press announcement. The products Mayne will acquire from Teva and Allergan include modified-release tablets and capsules, soft-gel capsules, and tra
6/29/16 - Studies from A. Hallersten and Co-Researchers Yield New Data on Biologics [Physicians prefer greater detail in the biosimilar label (SmPC) - Results...
According to news reporting originating from Brussels, Belgium, by NewsRx correspondents, research stated, "In the European Union, labels of biosimilars and their reference products are in many instances almost identical despite different data requirements for the authorization of biosimilars and generics. For more information on this research see:
6/29/16 - Therapeutic Antibody Reports Bundle 2016: Key Report on ADCs, Bispecifics, Biosimilars & Biosuperiors - Research and Markets
By a News Reporter-Staff News Editor at Biotech Week Research and Markets has announced the addition of the "Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars& Biosuperiors" report to their offering. Below are summaries of each report as well as links to purchase the individual titles: "Antibody-Drug Conjugates 2016: Perspective
6/28/16 - AMCP Launches Online Biosimilars Resource Center for Pharmacists, Physicians, Other Providers
ALEXANDRIA, Va., June 28, 2016/ PRNewswire-USNewswire/ The Academy of Managed Care Pharmacy is proud to announce the launch of the Biosimilars Resource Center, an unbiased, policy-neutral repository of educational resources and information on biosimilars for pharmacists, physicians, nurses and other health care providers. "Biosimilars are new to
6/28/16 - ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection USP, 250mg/mL
ANI Pharmaceuticals, Inc. today announced the commercial launch of Hydroxyprogesterone Caproate Injection USP 250 mg/mL in 5 mL vials. Arthur S. Przybyl, ANI's President and CEO stated, "The launch of HPC injection is ANI's seventh new product introduction this quarter. ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company d
6/28/16 - Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis
REDWOOD CITY, Calif., June 28, 2016 Coherus BioSciences, Inc., a leading global biosimilars company with late-stage clinical products, today announced that a study with CHS-131 in treatment-nave, relapsing remitting multiple sclerosis subjects demonstrated approximately a 50% decrease in the incidence of new contrast-enhancing lesions over six
6/28/16 - DGAP-News: amp biosimilars announces Klaus K. Wilgenbus as new CEO
DGAP-News: amp biosimilars AG/ Key word: Change of Personnel amp biosimilars announces Klaus K. Wilgenbus as new CEO 28.06. 2016/ 08:30 The issuer is solely responsible for the content of this announcement.- amp biosimilars announces Klaus K. Wilgenbus as new CEO- Experienced
6/28/16 - DGAP-News: amp biosimilars ernennt Klaus K. Wilgenbus zum neuen CEO
DGAP-News: amp biosimilars AG/ Schlagwort: Personalie amp biosimilars ernennt Klaus K. Wilgenbus zum neuen CEO 28.06. 2016/ 08:30 Fr den Inhalt der Mitteilung ist der Emittent verantwortlich.- amp biosimilars ernennt Klaus K. Wilgenbus zum neuen CEO- Erfahrener Branchenexpe
6/28/16 - Endo Announces Issuance of Vasostrict Patent
DUBLIN, June 28, 2016/ PRNewswire/ Endo International plc today announced that one of its operating companies, Par Pharmaceutical, has been issued a new patent by the U.S. Patent and Trademark Office relating to Vasostrict 20 units/mL. This Orange Book listing requires any Abbreviated New Drug Application applicant seeking FDA approval for a g
6/28/16 - Hetero launches colorectal cancer drug [Daily News Egypt]
Swiss healthcare giant Roche has filed a lawsuit in the Delhi High Court to prevent the launch of Bevacizumab in India but Hetero Drugs said that there no order against the company. "Roche has filed a lawsuit to block the launch of Hetero's Biosimilar Bevacizumab before the Honourable High Court. However the High Court has not given any injunction
6/28/16 - Lannett Receives FDA Approval For Diazepam Oral Solution, 5 mg/5 mL
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diazepam Oral Solution, 5 mg/5 mL, the therapeutic equivalent to the reference listed drug, Diazepam Oral Solution, 5 mg/5 mL, of Roxane Laboratories, Inc. According to IMS, total U.S. sales in
6/28/16 - Mayne Pharma expands into US for $889m [Palestine Chronicle, The]
Mayne Pharma is set to significantly expand its US presence through the$ US652 million acquisition of a suite of generic drugs from Teva Pharmaceutical Industries and Allergan. 'The acquisition transforms Mayne Pharma's generic products division into a top 25 player in the US retail generics market, diversifying Mayne Pharma's earnings across a bro
6/28/16 - Mayne Pharma raising $888m to fund US generics acquisition [UMCI News]
Mayne Pharma has cemented its status as one of Australia's fastest-growing companies by paying $887 million for a portfolio of generic drugs that will make it the second-largest drug maker on the stock exchange and one of the top 25 generic drug companies in North America. Adelaide- based Mayne Pharma has agreed to pay$ US652 million for 42 generic
6/28/16 - Mayne Pharma To Buy U.S. Generic Products From Teva, Allergan For $652 Mln
PETAH TIKVA- Australia's Mayne Pharma Group Ltd. said that it has entered into a binding agreement to acquire a portfolio of U.S. generic products from Teva Pharmaceutical Industries Limited and Allergan for cash consideration of $652 million. Completion of Mayne Pharma's acquisition is expected to be concurrent with the closing of Teva's acquisiti
6/28/16 - Navigating the complex biologics and biosimilars market
Release date- 27062016- Matt Regan, General Manager at AbbVie UK and Chair of the ABPI Biological Medicines Access Group blogs on the latest IMS Health report publication of IMS Health's updated report on' The Impact of Biosimilar Competition'. IMS Health's latest report on Biosimilars provides a valuable analysis of the impact of Biosimilar medici
6/28/16 - Teva and Antares Pharma Announce Launch of Generic Imitrex in the United States [Qatar Tribune]
Teva Pharmaceutical Industries Ltd., and Antares Pharma, Inc. today announced the launch of the generic equivalent to Imitrex1 injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the U.S. Sumatriptan injection is used to treat acute migraine with or without aura, and acute cluster headaches in adults. With approximately 370 ge
6/28/16 - Teva, Allergan sell product lines to Australian co [Globes, Tel Aviv, Israel]
June 28 Teva Pharmaceutical Industries Ltd. continues to sell product lines in order to obtain regulatory approval from the US Federal Trade Commission for its acquisition of the generics division of Allergan plc. Australian pharmaceuticals company Mayne Pharma has announced that it has agreed to buy a portfolio of US generic products from Teva a
6/27/16 - Amneal Pharmaceuticals Honored with Best Overall Generics Manufacturer Award by Healthcare Distribution Alliance
By a News Reporter-Staff News Editor at Pharma Business Week Amneal Pharmaceuticals announced the company was recently honored with the Distribution Industry Award for Notable Achievements in Healthcare for Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of More Than $100 Million by the Healthcare Distribution...
6/27/16 - Biosimilars Market Projected To Reach $41.7 Billion By 2024: Grand View Research, Inc.
The biosimilars market is expected to reach USD 41.7 billion by 2024, according to a new report by Grand View Research, Inc. The global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024. For the purpose of this study, the major countries considered are the U.S., Canada, the UK, Germany, India, China, B
6/27/16 - Biosimilars: Practical Tips and Regulatory Guidelines on Entering the Emerging Markets
New windows of opportunity in emerging markets such as China and India presented at Biosimilars Europe 2016. Interesting mix of scientists, legal and commercial folk Allergan LONDON, ENGLAND, UNITED KINGDOM, June 27, 2016/ EINPresswire.com/ SMi s have announced that their 7th annual industry respected conference, Biosimilars Europe, will fea
6/27/16 - Charles River Laboratories Acquires Blue Stream Laboratories
Charles River Laboratories International, Inc. today announced that it has acquired Blue Stream Laboratories, Inc. Combining Blue Stream with Charles River s existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and biosimilar development from characterization through...
6/27/16 - Dr. Reddy's to acquire product portfolio from TEVA for US Market
By a News Reporter-Staff News Editor at Pharma Business Week Dr. Reddy's Laboratories has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc to acquire a portfolio of eight Abbreviated New Drug Applications in the U.S. for $350 million in cash at closing. The acquisition of these ANDAs is
6/27/16 - Drug dealers of hope: Activists fight for access to life-saving Hepatitis C cure [FRANCE 24]
Hepatitis C, a liver disease, causes approximately 500,000 deaths every year. Luckily, there is a miracle cure patented by the American pharmaceutical giant Gilead. In India, meanwhile, local pharmaceutical companies are authorised by their government to make generic copies, and can provide the entire course of treatment for less then 5% of the usu
6/27/16 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 37601) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Arthritis Advisory Committee to discuss biologics license application 761042, for GP2015, a proposed biosimilar to Amgen Inc.' s ENBREL submitted by Sandoz, Inc., for the proposed indications of reducing signs and symptoms, inducing major clinical respo
Articles(s): 1 - 25 of 53     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415